Angelini Pharma announces the acquisition of two OTC products from Sanofi in Germany and Austria

Angelini Pharma announces the acquisition of two Sanofi CHC brands in Germany and Austria for a total of € 47 M.

The acquired products include BoxaGrippal® (ibuprofen/pseudoephedrine), an OTC brand that provides effective temporary relief from a range of cold and flu symptoms, and Heumann, a brand of medicinal teas for the treatment of conditions including mild bladder and kidney problems, cough and intestinal pain.
Boxagrippal® was launched by Boehringer Ingelheim in 2013, and today ranks at the top of its category (#4 in Germany and #3 in Austria).
Heumann teas have a strong tradition of more than 60 years in herbal medicinal preparations.

The acquisition of these products supports Angelini Pharma both in strengthening its position in the OTC market and in consolidating its presence in Germany and Austria.
Boxagrippal® and Heumann Teas will join the main brand Tantum®, which has been successfully marketed in the two above-mentioned countries for many years.